Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
50 hedge funds and large institutions have $147M invested in Karuna Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
32% more funds holding
Funds holding: 38 → 50 (+12)
12% less capital invested
Capital invested by funds: $167M → $147M (-$19.6M)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WT
Wellcome Trust
London,
United Kingdom
|
+$24.6M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$7.24M |
| 3 |
BlackRock
New York
|
+$5.32M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.06M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$16.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.04M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.51M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.2M |
| 5 |
Goldman Sachs
New York
|
-$1.53M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
51
Vivo Capital
Palo Alto,
California
| – | -$6.51M | -325,000 | Closed |
|
|
MIM
52
Monashee Investment Management
Boston,
Massachusetts
| – | -$2.2M | -110,000 | Closed |
|
|
53
Goldman Sachs
New York
| – | -$1.53M | -76,470 | Closed |
|
|
MWNA
54
Marshall Wace North America
New York
| – | -$1.01M | -50,325 | Closed |
|
|
LCM
55
Laurion Capital Management
New York
| – | -$1M | -50,000 | Closed |
|
|
GCP
56
GSA Capital Partners
London,
United Kingdom
| – | -$621K | -31,000 | Closed |
|
57
Wellington Management Group
Boston,
Massachusetts
| – | -$561K | -28,031 | Closed |
|
|
DIM
58
DC Investments Management
Mclean,
Virginia
| – | -$536K | -26,756 | Closed |
|
59
Norges Bank
Oslo,
Norway
| – | -$200K | -10,000 | Closed |
|
|
PIM
60
Partner Investment Management
San Francisco,
California
| – | -$116K | -7,219 | Closed |
|
|
FIA
61
FNY Investment Advisers
New York
| – | -$16K | -811 | Closed |
|
|
CCA
62
Catalyst Capital Advisors
Huntington,
New York
| – | -$6K | -310 | Closed |
|
KRTX Hedge Fund Activity: Q3 2019 in Review
50 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q3 2019, worth a combined $147M — down 12% from $167M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KRTX positions and 12 closed out — a net gain of 12 holders — while 7 added to existing stakes and 16 trimmed.
The largest buyer was Wellcome Trust, opening a new position worth an estimated $24.6M. The largest seller was Eventide Asset Management, cutting an estimated $16.3M.
- 50 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q3 2019, up from 38 in Q2 2019.
- Funds reported $147M of Karuna Therapeutics, Inc. Common Stock stock for Q3 2019, down 12% quarter-over-quarter.
- 24 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of +12 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q3 2019 was Wellcome Trust, an estimated $24.6M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q3 2019 was Eventide Asset Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2019.